McKesson (MCK) Tops Q1 EPS by 2c, Revenues Miss; Offers FY19 EPS Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. META
10. TLT

Go back to McKesson (MCK) Tops Q1 EPS by 2c, Revenues Miss; Offers FY19 EPS Outlook

McKesson (MCK) PT Lowered to $134 at Baird; Remains Sidelined

July 27, 2018 7:15 AM EDT

Baird lowered its price target on McKesson (NYSE: MCK) to $134.00 (from $141.00) while maintaining a Neutral rating. MCK claims in-line performance across all three segments. However, YY EBIT facts: U.S. +2% on easy/transitory prior-year comparison, EU -12%, Med-Surg flat, Other -8%. Three of... More

Pharma's middlemen see shares suffer as challenges grow

July 25, 2018 12:04 PM EDT

By Lewis Krauskopf

NEW YORK (Reuters) - Uncertainty over potential actions to reduce prescription drug costs and competitive threats have taken a toll this year on shares of companies in the U.S. pharmaceutical supply chain. They get their chance to change investor sentiment with quarterly earnings reports in the coming days.

Prescription drug wholesalers, drug store chains and pharmacy benefit managers generally have seen their stock prices tumble this year, even as the overall S&P 500 healthcare sector has gained 6 percent.

Six S&P 500 stocks - CVS Health Corp (NYSE:... More